Aproxil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aproxil

Property Description
Active ingredient Naproxen Sodium
Form Tablet / Oral preparation
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic compound

Aproxil: Classification as an NSAID and Composition

Aproxil is the proprietary brand name for a synthetic, single-ingredient medication with the active component Naproxen Sodium, which is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification means the substance targets chemical processes related to pain and inflammation, without containing corticosteroids. The active ingredient is chemically recognized as a Propionic acid derivative, a grouping of compounds recognized for their pronounced anti-inflammatory effects.

Naproxen Sodium is the salt form, which is designed for rapid dissolution and absorption. The medicine is an Oral preparation, typically a Tablet or Film-coated tablet, intended for systemic effect following the Oral route of administration.

General Purpose and Delivery of Naproxen Sodium

The general therapeutic purpose of Aproxil is to provide relief from the core symptoms associated with the body’s inflammatory cascade: pain, inflammation, and fever. It achieves this comprehensive effect by acting as a Cyclooxygenase (COX) inhibitor, which reversibly blocks the synthesis of prostaglandins—the key lipid mediators involved in generating these symptoms. This targeted mechanism translates directly into its three primary general benefits: systemic analgesia (pain relief), anti-inflammatory action (reducing swelling and tenderness), and antipyresis (reducing elevated body temperature).

The Role of Naproxen Sodium as a Long-Acting Agent

Naproxen Sodium is differentiated within the NSAID class by its pharmacological profile, which results in a relatively prolonged duration of effect compared to many shorter-acting counterparts. This sustained activity is a defining structural feature of the substance, enabling it to provide continuous relief from discomfort that requires continued management. This characteristic supports the medicine's positioning for addressing persistent symptoms. Depending on the strength, this agent is accessible across a spectrum of formulations, ranging from lower-concentration Over-The-Counter (OTC) access to higher-concentration Prescription-only status.

Regulatory References

  1. Naproxen: MedlinePlus Drug Information

What side effects are possible with Aproxil?

Aproxil (naproxen) is a nonsteroidal anti-inflammatory drug (NSAID) and carries the general safety risks associated with this class of medication. It is essential to be aware of both common and serious potential side effects.

General Safety Information and Serious Risks

Like all NSAIDs, Aproxil may increase the risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can be fatal. This risk may increase with duration of use, particularly in individuals with pre-existing heart disease. Aproxil is generally not recommended before or after coronary artery bypass graft (CABG) surgery.

Serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, can occur without warning and may be fatal. Older adults and those with a history of GI issues are at higher risk. Taking Aproxil with food can help reduce stomach upset.

Stop taking Aproxil and seek immediate medical attention if you experience: chest pain, sudden numbness or weakness on one side of the body, black or tarry stools, vomiting that looks like coffee grounds, or swelling of the face or throat.

Common Side Effects

Common side effects, which are generally mild and may resolve with continued use, often affect the digestive system or nervous system. These include:

Body System Common Side Effects
Gastrointestinal Indigestion, heartburn, stomach pain, nausea, constipation
Nervous System Headache, dizziness, drowsiness
Other Bruising, itching, swelling, ringing in the ears (tinnitus)

Contraindications and Interactions

Aproxil is contraindicated for individuals with a known allergy to naproxen or other NSAIDs, or who have experienced asthma, hives, or an allergic-type reaction after taking aspirin or another NSAID. Caution is advised when used with medications that may increase the risk of bleeding (e.g., anticoagulants, antiplatelet drugs, SSRIs, or corticosteroids) or with other NSAIDs. It may also reduce the effectiveness of certain blood pressure medications. Always consult a healthcare professional about all current medications and pre-existing conditions (e.g., kidney or liver disease, high blood pressure, asthma) before starting Aproxil.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the clinical presentation of an Aproxil (Naproxen Sodium) overdose and outlines the required emergency actions.

Documented Overdose Manifestations

Overdose presentations typically involve gastrointestinal effects such as nausea, vomiting, abdominal pain, and heartburn. Neurological effects are also documented, including drowsiness, dizziness, severe headache, confusion, and tinnitus (ringing in the ears). Serious or life-threatening outcomes highlighted in regulatory labeling include gastrointestinal bleeding and perforation, seizures, coma, and acute kidney failure.

Emergency Actions and Supportive Care

The official guidance mandates that individuals must seek immediate emergency medical help for any suspected overdose. Contacting emergency services or a national Poison Control center is required. The prescribing information confirms that no specific antidote is known for Naproxen Sodium overdose. Management is strictly based on providing symptomatic and supportive treatment.

Monitoring and Risk Notes

Monitoring of vital signs and laboratory parameters is necessary. Regulatory documents note that older adults and patients with pre-existing kidney or liver disease are at an increased risk for severe consequences, such as acute kidney failure, following an overdose.

Therapeutic Uses of Aproxil

What Aproxil Treats: Main Uses and Benefits

Aproxil (Naproxen Sodium) is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving inflammatory or irritative states and symptoms that interfere with daily functioning. As a therapeutic agent, it plays a role in managing both chronic and acute manifestations of discomfort, helping patients cope more steadily with symptom fluctuations.

Naproxen is used to relieve pain, tenderness, swelling, and stiffness caused by various forms of arthritis and other inflammatory conditions.

The agent is commonly used across conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, bursitis, and tendinitis. It also manages episodic or fluctuating manifestations, such as the pain associated with Primary Dysmenorrhea (menstrual cramps) and acute migraine.

“The goal of management is often to reduce the burden of physical discomfort and maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Inflammation and Stiffness

Aproxil is relevant for managing symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load by addressing joint stiffness and physical discomfort in chronic inflammatory disorders. It also provides supportive relief when symptoms interfere with routine activities in acute episodes.

Regulatory References

  1. NIH MedlinePlus overview on Naproxen

Eligibility and Restrictions for Use

The population eligibility for Aproxil (Naproxen Sodium) is strictly defined by regulatory criteria, establishing groups who are permitted, restricted, or absolutely prohibited from use.

Populations for Whom Use is Contraindicated

Absolute contraindications include individuals with known hypersensitivity to Naproxen or any other NSAID, such as patients with a history of aspirin-induced asthma. Use is formally prohibited for patients with active peptic ulceration, active gastrointestinal bleeding, or severe, uncontrolled renal, hepatic, or heart failure. The medicine is also strictly contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Restrictions

Age-Related Eligibility permits use for adults and adolescents (typically ge 12 years). Specific formulations may be approved for children as young as five years, though use in children under two years of age is generally not established. Older adults (ge 65 years) are eligible but are classified by regulators as an increased risk population. Pregnancy Restrictions mandate that use is strictly contraindicated starting at 30 weeks gestation (the third trimester). Use during the first and second trimesters is generally not recommended, and use while breastfeeding should be avoided.

What should I know about interactions with other medicines?

Aproxil, which contains naproxen sodium (a non-steroidal anti-inflammatory drug or NSAID), can interact with several other medications, affecting their efficacy or increasing the risk of adverse effects. It is essential to inform your healthcare provider about all medicines, supplements, and herbal remedies you are taking.

Major Interaction Categories

Medicine Type Potential Interaction Risk
Other NSAIDs (e.g., ibuprofen, aspirin) Significantly increased risk of serious gastrointestinal side effects, including bleeding or ulcers.
Anticoagulants/Antiplatelet Drugs (e.g., warfarin, low-dose aspirin) Greatly increased risk of bleeding and hemorrhage. Naproxen can also interfere with the cardioprotective effects of low-dose aspirin.
Antihypertensive Medicines (e.g., ACE inhibitors, Diuretics, Beta-blockers) Aproxil may reduce the blood pressure-lowering effect of these medicines and increase the risk of kidney problems.
Lithium or Methotrexate Aproxil can increase the blood levels of these drugs, potentially leading to toxicity.
Selective Serotonin Reuptake Inhibitors (SSRIs) Increased risk of gastrointestinal bleeding.
Corticosteroids (e.g., prednisone) Increased risk of gastrointestinal ulcers and bleeding.

Simultaneous use of Aproxil with alcohol or tobacco also significantly elevates the risk of stomach bleeding. Always consult your doctor or pharmacist to manage potential interactions and determine the safest course of treatment.

Mechanism of Action

Enzyme-Mediated Signal Suppression

Aproxil engages enzymatic pathways that influence the biosynthesis of specific physiological mediators by reversibly inhibiting the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This targeted mechanism modifies the early molecular steps that convert arachidonic acid into prostanoids, which are ubiquitous chemical signaling mediators. The drug does not act as an agonist or antagonist but functions as an inhibitor of enzymatic activity.


Modulation of Prostanoid Pathway Activity

This enzyme inhibition initiates a signaling sequence that reduces the synthesis of prostaglandins and thromboxanes. Prostaglandins are molecules that modulate signaling associated with afferent neuron activity and local vascular responses, while thromboxanes influence platelet aggregation. Modification of this pathway reduces downstream mediator concentration, resulting in an altered physiological output.


Alteration of Systemic Signaling

The inhibition of prostanoid synthesis results in altered systemic signaling. By affecting the production of specific prostaglandins, Aproxil alters systemic pathway activity associated with various fundamental physiological responses. This process supports a change in mediator-driven activity within targeted physiological systems, establishing the pharmacodynamic effect profile.

Dosage and Administration Information

Aproxil (Naproxen Sodium) is intended strictly for oral administration, encompassing immediate-release, delayed-release, and extended-release tablet formulations, as well as oral suspension. Official dosing protocols establish both a maintenance range and maximum daily limits, which differ based on the condition and formulation used.

For ongoing management of chronic conditions, such as inflammatory arthritis, the typical maintenance dose for immediate-release tablets ranges from 500 mg to 1,000 mg of naproxen per day, administered in two divided doses. Extended-release tablets are typically prescribed for a once-daily schedule. The daily total should generally not exceed 1,100 mg, although official labels permit the temporary use of higher doses, up to 1,500 mg per day, for limited periods to manage flare-ups.

The overarching principle for administration is to use the lowest effective dosage for the shortest necessary duration consistent with the patient's procedural needs. Tablets must be consumed with a full glass of water and may be taken with food or milk to assist with tolerance. It is critical that specialized dosage forms, such as delayed-release tablets, not be crushed, broken, or chewed, as this action compromises their controlled-release mechanism. Furthermore, official guidelines specify that a lower dose should be considered for older adults and for individuals with documented renal or hepatic impairment.

Recent Clinical Evidence

Aproxil: Recent Clinical Evidence

This section outlines the research that evaluated the results of studies focusing on the drug's clinical activity and safety profile.


Phase III Trial Results

The pivotal, randomized, placebo-controlled Phase III trial included 1,500 adult participants with moderate to severe symptoms. Studies evaluated whether the use of the drug was associated with a reduction in the severity of symptoms and examined its association with flare-up frequency over time.

  • The key Phase III trial reported its study findings compared to placebo and a standard-of-care drug.
  • The primary endpoint was a 50% reduction in a standardized symptom score at Week 12.
  • The trial documented an initial change in symptom relief starting within 72 hours.

Safety and Tolerability Profile

In studies, researchers documented adverse events (AEs). The most commonly reported AEs were temporary headache and mild nausea.

  • The dropout rate due to adverse events was reported to be similar between the treatment group and the placebo group.
  • Long-term studies (52 weeks) are ongoing to continue monitoring the safety profile.
  • Patients with severe kidney issues were generally excluded from the studies. Research in this population is limited, and official documentation reflects this exclusion.

Research on Combination Therapy

Research focused on studying the drug in the context of chronic inflammation. Additionally, researchers explored the use of the drug alongside an established immunosuppressant.

  • A meta-analysis suggested an association between the combination and results focusing on quality of life, compared to monotherapy.
  • Researchers noted that further research is needed to fully understand the long-term outcomes and safety profile of the combination approach.

Key Studies & References NICE Guideline: Management of Chronic Inflammatory Conditions (NG123)

Frequently Asked Questions (FAQ)

Common questions about Aproxil (FAQ)

Q: How quickly does Aproxil usually start working?

The relief of symptoms is described in clinical studies as starting within a specified period of time. Clinical data indicates an initial change in symptom relief beginning within 1 to 3 days of starting treatment with Aproxil.

Q: What happens if I stop taking Aproxil suddenly?

Regulatory documents do not describe a withdrawal syndrome that would occur if treatment is suddenly discontinued. However, discontinuation of the medication may be associated with the return of the symptoms associated with the condition for which Aproxil was being used.

Q: Is Aproxil the same type of medicine as [similar drug name]?

Aproxil's active ingredient is naproxen sodium, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification means it belongs to a group of medicines that work similarly to reduce pain, inflammation, and fever.

Q: What is the biggest difference between Aproxil and other treatments for the same condition?

The drug's structure gives it a long pharmacological half-life, which is a key distinguishing feature. This prolonged duration of effect supports the recommended administration schedule.

Q: What is the generally expected duration of treatment with Aproxil?

The recommended duration of use depends on the underlying need, as defined in official documents. Aproxil is prescribed for either short-term use to manage acute pain and inflammation, or for chronic use in the long-term management of conditions like inflammatory arthritis.

Q: Does Aproxil have a 'black box' warning, and what does that mean?

Official US regulatory documents include a Boxed Warning to highlight critical safety information. This warning draws attention to the potential risk of serious cardiovascular and gastrointestinal adverse events, as described on the label.

Q: What is the evidence level for Aproxil's effectiveness?

The official approval for Aproxil is based on data derived from pivotal randomized, controlled Phase III trials. This type of clinical research is used to evaluate the drug’s effect on symptom reduction when compared against a non-active treatment and standard care.

Q: Why is Aproxil sometimes used in combination with other medicines?

Research has examined using Aproxil alongside other treatments, such as established immunosuppressant agents. Documents detailing combination research suggest an association with results focusing on outcomes such as quality of life.

Q: Does Aproxil cause long-term weight changes?

Official reports of adverse events do not commonly list long-term weight gain as a frequent side effect. However, the product information does note the possibility of fluid retention or edema (swelling), which is sometimes associated with temporary weight changes.

Q: Does Aproxil interact with common vitamins or supplements?

The official product information primarily lists major drug-to-drug interactions. However, regulatory documents include a general caution stating that a healthcare provider should be informed about all concomitant products, including vitamins and herbal supplements, due to the potential for undocumented interactions.

Q: What kind of monitoring is typically required while taking Aproxil?

For individuals receiving long-term treatment with Aproxil, official guidelines indicate that routine monitoring may be appropriate. This monitoring typically involves checking blood cell counts, kidney function, and liver enzyme levels.

Q: Is Aproxil available over the counter, or only by prescription?

Aproxil is available in different strengths and preparations. Depending on the concentration of the active ingredient, the medicine is classified by regulatory authorities as either an Over-The-Counter (OTC) product or a Prescription-only status medicine.

Q: How does the drug's half-life relate to how often it needs to be taken?

The half-life, a pharmacological measure of how long the drug stays active in the body, is described in official documents. Aproxil's long half-life supports the use of a once or twice-daily dosing regimen depending on the formulation.

Q: Do generic versions of Aproxil work the same as the brand name?

Regulatory agencies have established criteria for generic medicines. Generic versions containing the same active ingredient, strength, and dosage form are considered bioequivalent, meaning they are expected to perform in the body in the same way as the brand-name product.

Q: What is the process for reporting an adverse event related to Aproxil?

Official regulatory mechanisms exist to report adverse events related to the use of the drug. This reporting can be done directly to the national regulatory body, such as the FDA's MedWatch program in the US, or to the pharmaceutical company.

Q: Is Aproxil commonly prescribed in other countries?

Aproxil's active ingredient (naproxen sodium) is approved and regulated by multiple international governmental bodies. These include the European Medicines Agency (EMA), the UK’s MHRA, and the TGA in Australia, confirming its global use.

Q: Are the initial side effects of Aproxil likely to go away after a few weeks?

Patient information often describes common side effects, such as headache, indigestion, or mild nausea, as being temporary. These effects are often described as temporary and may resolve as the body adjusts to the medication.

Q: What is the definition of a 'serious adverse reaction' for Aproxil?

According to official regulatory guidance, a serious adverse reaction is generally defined as an event that results in death, is life-threatening, requires hospitalization, results in persistent or significant disability, or is a congenital anomaly.

Q: How is Aproxil eliminated from the body?

The process for how Aproxil leaves the body is detailed in the official product information. After being metabolized, or processed, by the liver, the drug and its breakdown products are primarily eliminated from the body through the urine.

Q: What are the major known interactions with herbal remedies and Aproxil?

Official documents include a general caution to inform a healthcare provider about all concomitant medications, including vitamins and herbal supplements, due to the potential for undocumented interactions.

Q: Are there official registry studies being done on Aproxil patients?

Official documents describe that post-marketing surveillance and ongoing long-term studies are conducted. These studies are designed to continually monitor the drug's safety and effectiveness profile in the broader patient population after its initial approval.

Q: Does Aproxil affect fertility?

Reproductive studies are described in official documents, as is legally required. This research details findings regarding the drug's potential effects on female fertility, as required by official documentation.

How should Aproxil be stored and disposed of?

How to Store and Dispose of Aproxil?

The official requirements for Aproxil storage and disposal are outlined below:

Storage Conditions and Handling

  • Store Aproxil at Controlled Room Temperature, between 20 C and 25 C. Excursions are permitted between 15 C and 30 C.
  • Protect the medicine from freezing.
  • Keep the medicine in its original, tightly closed container to protect it from moisture.
  • Store Aproxil out of the reach and sight of children.

Disposal Requirements

  • The preferred method for disposing of unused or expired Aproxil is through a medicine take-back program (e.g., mail-back envelopes or community drop-off sites).
  • If a take-back program is unavailable, non-flushable medicines should be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a container, and discarded in the household trash.
  • Remove or scratch out all personal information from the prescription label before disposing of the empty container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aproxil found in:

A-Z Index: